Psoriasis and psoriasis arthritis: board meeting of the Rising project

Psoriasis: current model of pathophysiology showing the involvement of IL-23 and IL-17 in the inflammatory phenomenon

Maxer, in collaboration with Aristea, coordinated the Rising project, a cycle of Board Meetings promoted by AbbVie and dedicated to two main themes:

• the effects of psoriasis at the level of social stigma, comorbidity, coping strategies and external factors, better known as Cumulative Life Course Impairment (CLCI)
• the evolution of psoriasis towards psoriatic arthritis.

The project foresaw three meetings held between February and June and attended by 17 dermatologists from all over Italy. Maxer moderated the debates and wrote the slide decks and minutes of the meetings.
Divided into two groups, the dermatologists explored the themes of the project, highlighting the critical issues associated with the pathologies and the therapeutic opportunities deriving from monoclonal antibodies, such as risankizumab, in the management of psoriasis and the prevention of psoriatic arthritis. Risankizumab consists of an immunoglobulin G1 (IgG1), selective for the protein interleukin 23 (IL-23) and is indicated for:

• the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy;
• the treatment, alone or in combination with methotrexate (MTX), of active psoriatic arthritis in adults who have had an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs).